Shield Therapeutics PLC PDMR Acquisition of Shares and Additional Listing (5467W)
April 17 2019 - 12:01PM
UK Regulatory
TIDMSTX
RNS Number : 5467W
Shield Therapeutics PLC
17 April 2019
Shield Therapeutics plc
("Shield" or the "Company")
PDMR Acquisition of Shares and Additional Listing
London, UK, 17 April 2019. Shield Therapeutics plc (LSE:STX), a
commercial stage pharmaceutical company with a focus on addressing
iron deficiency with or without anaemia via its lead product
Feraccru(R), announces that it issued and allotted 223,690 Ordinary
Shares of 1.5p each following the exercise of options under the
Shield Therapeutics plc 2016 Long-Term Incentive Plan and the
Shield Therapeutics Retention and Performance Share Plan.
Carl Sterritt, Chief Executive Officer of the Company, has on 16
April 2019 exercised options held under The Shield Therapeutics plc
2016 Long-Term Incentive Plan to acquire 123,690 Ordinary Shares in
the Company. Following the transaction, Mr Sterritt holds
10,198,951 shares, representing 8.71% of the Company's issued share
capital. The remaining 100,000 Ordinary Shares were allotted
following the exercise of options by other staff members.
Application has been made to the London Stock Exchange for the
new Ordinary Shares to be admitted to trading on AIM. Admission is
expected to be effective on 25 April 2019. The Ordinary Shares
shall rank pari passu with the existing ordinary shares in the
Company.
Following admission, the Company's issued share capital will
comprise 117,041,488 Ordinary Shares and each Ordinary Share
carries one vote. There are no Ordinary Shares held in treasury and
accordingly, the total number of voting rights is 117,041,488. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Carl Sterritt
------------------------- ------------------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status CEO and Director of Shield Therapeutics plc
------------------------- ------------------------------------------------
b) Initial Initial Notification
notification/
Amendment
------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Shield Therapeutics plc
------------------------- ------------------------------------------------
b) LEI 213800G74QWY15FC3W71
------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description Ordinary shares of 1.5p each in the capital
of the of the Company
financial ISIN of Ordinary Shares: GB00BYV81293
instrument,
type of
instrument
Identification
code
------------------------- ------------------------------------------------
b) Nature Exercise of share options held under The Shield
of the Therapeutics plc 2016 Long-Term Incentive Plan
transaction to acquire Ordinary Shares in the Company.
------------------------- ------------------------------------------------
c) Price(s) 1.5p per Ordinary Share
and volume(s) Volumes: 123,690
------------------------- ------------------------------------------------
d) Aggregated
information 123,690
GBP1,855.35
* Aggregated volume
* Price
------------------------- ------------------------------------------------
e) Date of 16 April 2019
the transaction
------------------------- ------------------------------------------------
f) Place Outside a trading venue
of the
transaction
------------------------- ------------------------------------------------
Shield Therapeutics plc www.shieldtherapeutics.com
Carl Sterritt, Chief Executive
Officer +44 (0)20 7186 8500
Tim Watts, Chief Financial Officer
Nominated Advisor and Broker
Peel Hunt LLP
James Steel/Dr Christopher Golden +44 (0)20 7418 8900
Financial PR & IR Advisor
Walbrook PR +44 (0)20 7933 8780 or shield@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7841 917
Paul McManus / Helen Cresswell 679
About Shield Therapeutics plc
Shield is a de-risked, commercial stage, pharmaceutical company
delivering innovative specialty pharmaceuticals to address
patients' unmet medical needs. The Company's clear purpose is to
help its patients become people again, by enabling them to enjoy
the things that make the difference in their everyday lives. The
Group has a marketed product, Feraccru(R), for the treatment of
iron deficiency in adults which has exclusive IP rights until the
mid-2030s. Feraccru(R) is commercialised in the European Union by
Norgine BV and the US Food and Drug Administration (FDA) is
currently considering a New Drug Application (NDA), with a PDUFA
(Prescription Drug User Fee Act) date of 27(th) July 2019. For more
information please visit www.shieldtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements. These forward-looking statements are based on
management's current expectations and include statements related to
the timing of future results of Feraccru trials and the timing and
success of the Group's regulatory plans and commercial strategy for
Feraccru. These statements are neither promises nor guarantees, but
involve known and unknown risks and uncertainties, many of which
are beyond our control, that may cause actual results, performance
or achievements to be materially different from management's
expectations expressed or implied by the forward-looking
statements, including, but not limited to, risks associated with
the regulatory approval process, the Group's business and results
of operations, competition and other market factors. The
forward-looking statements made in this press release represent
management's expectations as of the date of this press release, and
except as required by law, the Group disclaims any obligation to
update any forward-looking statements contained in this release,
even if subsequent events cause our views to change.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHEASLXFSPNEFF
(END) Dow Jones Newswires
April 17, 2019 12:01 ET (16:01 GMT)
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Shield Therapeutics (LSE:STX)
Historical Stock Chart
From Jul 2023 to Jul 2024